Antitumor reactivity of anti- XXXX /anti- @entity10867 bead-activated lymphoid cells: implications for cell therapy in a @entity19 model.

@entity2304 @entity2047 @entity19 @entity5 @entity5168 @entity60 @entity1618 @entity10867 @entity1961
Ligation of TCR and @entity10867 expressed on T cells via mAbs results in activation of T cells capable of @entity5 destruction in adoptive immunotherapy. In a @entity19 model, the authors examined in vitro activation conditions utilizing plate-immobilized and bead-conjugated mAbs that bind to @entity5168 and @entity10867 . Bead-activated @entity5 -draining lymph node (TDLN) cells demonstrated superior cytokine ( @entity60 , @entity2304 , @entity2047 , and @entity1618 ) secretion and mediated @entity5 regression more efficiently compared with plate-activated cells. The bead-activated TDLN cells had a significantly higher percentage of @entity1961 + cells compared with plate-activated cells. On a per-cell basis, positively selected @entity1961 + cells activated with bead-coupled or plate immobilized mAbs mediated @entity5 -specific regression equally. Bead-activated @entity1961 + TDLN cells demonstrated significantly higher levels of @entity5 specific @entity2047 secretion compared with plate-activated @entity1961 + cells that may provide helper function to CD8+ effector cells. The antitumor reactivity of bead-activated lymphoid cells depended upon their source. TDLN cells after bead activation were more potent than splenocytes from @entity5 -bearing hosts in mediating @entity5 regression in vivo. Bead-activated LN cells and splenocytes from nontumor-bearing hosts demonstrated nonspecific cytokine secretion and minimal efficacy in adoptive immunotherapy. At minimal doses of @entity2047 , the antitumor reactivity of bead-activated TDLN cells was significantly enhanced. Anti- @entity5168 /anti- @entity10867 bead activation of @entity5 -primed T cells represents an efficient method to generate effector cells for immunotherapy.
